Atlantic Health Strategies

Newport Healthcare’s Third Restructuring in a Year: What PE-Backed Behavioral Health Operators Should Read Into It

Table of Contents

Ready to See Results?

From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.

The Newport file, and what buyers are actually repricing

Newport Healthcare’s third restructuring in roughly 12 months, a CEO replacement plus layoffs plus site closures, tells PE-backed and independent behavioral health operators that multiples are compressing and buyers are repricing deals around utilization risk, payer concentration, and compliance debt. Founders eyeing exit should stress-test unit economics now and plan for EBITDA multiples below the frothy 2021 range that produced Newport’s own $1.3 billion Onex transaction.

Behavioral Health Business reported last week that Brian Setzer, who became CEO on Dec. 9, 2024, will be replaced by his predecessor, Joe Procopio, who started as CEO in June 2019, with Procopio leading alongside CFO-turned-president Brian Heinrichs. The staffing cuts are not small. On Tuesday, 104 administrative staff members were told they would be let go, and in the last few weeks at least 100 more roles have been impacted, including 40 staff at five home-based residential treatment facilities in Ventura County, California, with the Waukesha, Wisconsin location shuttering its intensive outpatient and partial hospitalization programming.

This is the sequel to a bigger pullback. In October 2025, Newport closed nine residential facilities located in large homes in residential areas, five in Northern California, three in Southern California and one in Virginia, and also closed its office in Irvine, California. The sponsor economics confirm the stress. Newport Healthcare is majority-owned by Onex Corp. Via its Onex Partners V fund, which acquired its stake in 2021; Onex’s 2024 financial report stated that its investment in Newport Healthcare decreased in value, and the same report states that Onex holds a 23% economic interest and a 92% voting interest in the company.

Deal volume and multiples: the math buyers are using now

Pull quote: PE-backed mental health M&A deals plummeted from 15-20 typical quarterly to just 5 in Q2 2024.

Operators planning an exit need to look at what actually traded, not what traded four years ago. Mertz Taggart’s Q2 2024 report noted that transaction activity across behavioral healthcare in the second quarter was marked by growth funding continuing to flourish while mergers and acquisitions dipped to early COVID-19 pandemic levels, with 30 total deals reported, down nearly a third from the 44 announced in the year’s first three months. The pullback was concentrated where it hurts sellers most. The 19 true M&A transactions reported in Q2 were the fewest since the onset of the pandemic in Q2 2020, driven by a decline in private equity-backed portfolio company acquisitions; a typical quarter sees about 15 to 20 PE-backed strategic deals, and in Q2 just 5 such transactions were announced.

Mental health specifically has thinned out. Deal volume has declined significantly from 2022, when 42 mental health transactions were reported in the third quarter alone, compared with just 19 such deals announced in Q3 of 2024. Mertz Taggart managing partner Kevin Taggart put the sentiment plainly: “It’s gotten tougher to get deals done in the second half of this year, and the numbers would certainly reflect that.”

The 2024 close was softer than headlines suggested. A total of 37 transactions, 26 traditional M&A deals and 11 growth deals, were reported in Q4 2024, bringing the total for the year to a combined 155 transactions. While there is still demand for medical outpatient and psychiatry practices, valuations for outpatient mental healthcare facilities have come down slightly, and demand for counseling-only practices is down as well. Buyers are hunting medical, in-network, utilization-defensible platforms. Residential youth operators carrying out-of-network revenue and real estate overhead are the ones being asked to defend their model line by line.

The diligence binder Newport's story should force you to rebuild

Here is the operator-side read. When a platform originally valued at adjusted EBITDA projected to come in north of $80 million for 2021, with trailing 12-month EBITDA in the low $70 million range ends up closing nine residential homes, exiting the San Francisco market, and swapping CEOs twice inside a year, the diligence failure was usually not clinical. It was payer mix, real estate concentration, and in-network readiness.

Newport itself has signaled the pivot. In the October 2025 announcement the company said it was focused on growing its operations in Connecticut, Massachusetts, Minnesota and Utah, and a spokesperson framed the move as a way “to secure more in-network contracts for families”. That is a late-stage admission that the housing-based, cash-pay-adjacent model does not survive commercial payer discipline at scale.

What AHS tells buyers and sellers to pull before they sign anything:

  • Payer mix stress test by level of care. Model what happens to EBITDA if commercial residential reimbursement drops 10%, 15%, 20%. If the pro forma breaks at 10%, you do not have a platform, you have a book of business.
  • Parity audit scope under MHPAEA. The Department of Labor and HHS have been enforcing the Mental Health Parity and Addiction Equity Act with teeth. Buyers should see the seller’s NQTL comparative analysis, every denial appeal log for the last 24 months, and any payer-specific utilization management correspondence.
  • Licensing survey history pull from every state agency. Not a summary. The actual Statements of Deficiency, plans of correction, and reinspection reports from Florida AHCA, Virginia DBHDS, Minnesota DHS, Utah DHHS, and every other state where the seller operates. This is where “compliance debt” lives.
  • CARF or Joint Commission survey window posture. Where is the seller in the three-year cycle, what were the last surveyor focus areas, and did any finding roll into a conditional accreditation?
  • OIG and DOJ exposure review. Public enforcement calendars, SIU audit correspondence from commercial payers, and any CID the seller has received. False Claims Act settlements in behavioral health are not rare anymore, and successor liability is a real pricing input.
  • ASAM Criteria 4th Edition level-of-care documentation audit. Pull a stratified sample of charts across residential and outpatient levels. If the clinical team is still citing the 3rd edition’s level numbers in medical necessity letters, that is a payer denial exposure buyers will discount for.

Why the sponsor side matters, and what it tells independents

Onex’s acquisition of Newport was not a stretch deal when it closed. The 2021 behavioral health market was absorbing capital at historic levels. U.S.-based private equity firms continue to sit on a significant amount of “dry powder,” nearly $1 trillion in funds that need to be spent or returned to investors, and healthcare services, particularly behavioral healthcare, remain very attractive, Mertz Taggart Managing Partner Kevin Taggart said. That dry powder has not disappeared, but the thesis has sharpened. Buyers want in-network revenue, medical acuity, and licensure portability. They do not want out-of-network residential homes in high-cost real estate markets.

Independent operators should read the Newport sequence as free consulting. Onex Corp. Acquired Newport in July 2021 and holds a 23% economic and 92% voting interest; the company’s latest annual report states that its value decreased in 2025 and 2024. When a sponsor marks down a flagship platform two years running, every comparable platform’s exit multiple moves. Advisors see it in LOIs within a quarter.

What AHS watches on the sponsor side during a sell-side process: how recently did the fund mark down comparable assets, what is the fund’s remaining life, and how many portfolio companies in the same vertical are stacked behind yours in the exit queue. If three PE-backed residential platforms try to exit in the same 18-month window, the fourth seller takes the discount.

Pull quote: When a sponsor marks down a flagship asset twice, every comparable exit multiple moves.

Frequently asked questions

What are current EBITDA multiples for residential behavioral health platforms in 2024-2025?
Platform-scale residential behavioral health traded in the 10 to 14 times EBITDA range at the 2021 peak. In the current market, Mertz Taggart’s commentary and public mark-downs on comparable assets suggest meaningful compression, particularly for out-of-network and youth residential models. Published multiples vary by subsegment, but valuations for outpatient mental healthcare facilities have come down slightly, and demand for counseling-only practices is down as well. Expect buyers to price risk, not growth, until deal volume normalizes.

How do buyers assess compliance debt during behavioral health diligence?
They pull the actual regulator record. State licensing survey histories from agencies like Florida AHCA, Virginia DBHDS, Minnesota DHS, and Utah DHHS. Accreditation history from The Joint Commission or CARF International including any conditional or probational status. SAMHSA correspondence if the operator holds a federal grant or OTP certification. OIG exclusion checks on every clinician. Any CID or SIU audit letters. Compliance debt is the gap between what the policy manual claims and what the regulator record actually shows.

What due diligence red flags predict post-close restructuring like Newport’s?
Concentration risk in one real estate footprint, high out-of-network revenue share, census volatility quarter over quarter, denial rates above payer-market norms, pending MHPAEA complaints, and ASAM Criteria documentation that does not match the billed level of care. Also: founder-led clinical leadership with no deep bench. When a platform cannot replace its chief medical officer or chief compliance officer in 90 days, that is an integration risk buyers underwrite into the price.

Should founders delay exit until multiples recover, or sell into a buyer’s market?
It depends on your covenant posture and sponsor timeline. If you have 18 months of runway and clean compliance, waiting may improve the outcome, especially if payer contracting and census are trending up. If you have covenant pressure, pending licensure issues, or a sponsor nearing fund-life end, selling now at a disciplined price beats selling later from a position of distress. Newport’s trajectory shows what happens when a platform tries to shrink into profitability under public scrutiny.

How does payer concentration risk affect valuation in a residential MH/SUD platform?
A platform with any single commercial payer above roughly 25 percent of net revenue gets discounted. Buyers model the scenario where that payer renegotiates rates, tightens utilization management, or terminates the contract. If the residential length of stay average depends on one payer’s current authorization pattern, the EBITDA is not durable. The fix is diversified in-network contracting across at least three major carriers per state before you go to market.

Request a Free Consultation

Scroll to Top